Effect of Enoxaparin Sodium Combined with Low Molecular Weight Heparin Calcium on PIGF and sFlt-1 Levels in Patients with Severe Preeclampsia
Objective To study the effect of enoxaparin sodium combined with low molecular weight heparin calcium on the levels of placental growth factor (PIGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in patients with severe preeclampsia. Methods A total of 62 patients with severe preeclampsia diagnosed and treated in our hospital from May 2022 to October 2023 were selected as the research objects. They were divided into routine group and study group by random number table method,with 31 patients in each group. The routine group was treated with low molecular weight heparin calcium,and the study group was treated with low molecular weight heparin calcium+enoxaparin sodium. The therapeutic effect,coagulation function indexes[D-dimer (D-D),fibrinogen (FIB),activated partial thromboplastin time (APTT),prothrombin time (PT)],PIGF,sFlt-1 levels,incidence of maternal complications and fetal adverse outcomes were compared between the two groups. Results The total effective rate of treatment in the study group (96.77％) was higher than that in the routine group (80.65％) (P<0.05). After treatment,APTT and PT in the two groups were higher than those before treatment,D-D and FIB were lower than those before treatment,and APTT and PT in the study group were higher than those in the routine group,D-D and FIB were lower than those in the routine group (P<0.05). After treatment,PIGF in the two groups was higher than that before treatment,sFlt-1 was lower than that before treatment,and PIGF in the study group was higher than that in the routine group,sFlt-1 was lower than that in the routine group (P<0.05). The incidence of maternal complications in the study group (6.45％) was lower than that in the routine group (19.35％) (P<0.05). The incidence of fetal adverse outcomes in the study group (3.23％) was lower than that in the routine group (16.13％) ( P<0.05).Conclusion Enoxaparin sodium combined with low molecular weight heparin calcium is effective in the treatment of severe preeclampsia. It can improve the therapeutic effect and PIGF level of patients,reduce the level of sFlt-1,improve coagulation function,prevent maternal complications,improve fetal adverse outcomes,and have a positive impact on mothers and infants.
万方数据
维普
